Skip to main content
Get Started
Videos
MS Hope's mission, dietary insights, and lifestyle strategies.
Checklists
Checklists on Best Bet Diet and supplements.
Science
12 Scientific Papers to Share With Your Doctor, Friends and Family.
Cookbook
125 Gluten-Free & Dairy-Free Recipes.
Documentary
Podcast
FAQ
Library
Store
Team
EN
EN
FR
Donate
Library
Journal Articles
Drugs
Research Library
Drugs
137 papers
Drugs
March 2009
The curious incident of disability in multiple sclerosis trials
Alasdair Coles
Drugs
March 2009
The protease inhibitor, Bowman_x0001_Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis: a potential oral therapy for multiple sclerosis
B. Gran, N. Tabibzadeh, A. Martin, E.S. Ventura, J.H. War...
Drugs
March 2009
Toward the Development of Rational Therapies in Multiple Sclerosis: What Is on the Horizon?
Bernhard Hemmer, Hans-Peter Hartung
Drugs
March 2009
Natalizumab and Immune Cells
Henry F. McFarland, Steven Jacobson
Drugs
March 2009
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring
Ludwig Kappos, David Bates, Hans-Peter Hartung, Eva Havrd...
Drugs
March 2009
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
Ludwig Kappos, Jack Antel, Giancarlo Comi, Xavier Montalb...
Drugs
March 2009
Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study
Ludwig Kappos, Mark S. Freedman, Chris H. Polman, Gilles ...
Drugs
March 2009
How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
M.G. Brown, S. Kirby, C. Skedgel, J.D. Fisk, T.J. Murray,...
Drugs
March 2009
Altered CD4_x0001_/CD8_x0001_ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis
Olaf Stüve, Christina M. Marra, Amit Bar-Or,Masaaki Niino...
Drugs
March 2009
Interferon beta in multiple sclerosis: how much BENEFIT?
Sean J. Pittock
Drugs
March 2009
The elephant in the room
Drugs
March 2007
Lessons for clinical trials from natalizumab in MS
Abhijit Chaudhuri
Drugs
March 2007
Selective Treatment of Multiple Sclerosis
Allan H. Ropper
Drugs
March 2007
What went wrong in the natalizumab trials?
Annette Langer-Gould, Lawrence Steinman
Drugs
March 2007
Regulatory CD56bright natural killer cells mediate immunomodulatory effects of IL-2R_x0001_-targeted therapy (daclizumab) in multiple sclerosis
Bibiana Bielekova, Marta Catalfamo, Susan Reichert-Scrivn...
Drugs
March 2007
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Chris H. Polman, Paul W. O’Connor, Eva Havrdova, Michael ...
Drugs
March 2007
High-Dose Cyclophosphamide for Moderate to Severe Refractory Multiple Sclerosis
Douglas E. Gladstone, Kenneth W. Zamkoff, Lauren Krupp, R...
Drugs
March 2007
Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis
E. M. Frohman, E. Havrdova, F. Lublin, F. Barkhof, A. Ach...
Drugs
March 2007
Therapeutic Considerations for Disease Progression in Multiple Sclerosis
Elliot M. Frohman, Olaf Stüve, Eva Havrdova, John Corboy,...
Drugs
March 2007
Interferon beta babies
Emmanuelle Waubant, A. Dessa Sadovnick
Drugs
March 2007
History of modern multiple sclerosis therapy
Fred Lublin
Drugs
March 2007
Severe anaphylactic reaction to glatiramer acetate with specific IgE
H. Rauschka, C. Farina, P. Sator, S. Gudek, F. Breier, M....
Drugs
March 2007
Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
Jason Ramtahal, Anu Jacob, Kumar Das, Mike Boggild
Drugs
March 2007
Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment
K.G. Warrena, I. Catza, L.Z. Ferenczib, M.J. Krantz
Drugs
March 2007
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
L. Kappos, C.H. Polman, M.S. Freedman, G. Edan, H.P. Hart...
Drugs
March 2007
The coming of age for antigen-specific therapy of multiple sclerosis
L. Steinman
Drugs
March 2007
Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis
M. Sandberg-Wollheim, D. Frank, T.M. Goodwin, B. Giesser,...
Drugs
March 2007
Can super-antibody drugs be tamed?
Michael Hopkin
Drugs
March 2007
Economic evaluation of Avonex† (interferon beta-1a) in patients following a single demyelinating event
Michael Iskedjian, John H. Walker, Trevor Gray, Colin Vic...
Drugs
March 2007
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
P.W. O’Connor,D. Li, M.S. Freedman, A. Bar-Or, G.P.A. Ric...
Drugs
March 2007
Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
Paul O’Connor, David Miller, Katherine Riester, Minhua Ya...
Drugs
March 2007
The reproductive effects of beta interferon therapy in pregnancy
R. Boskovic, R. Wide, J. Wolpin, D.J. Bauer, G. Koren
Drugs
March 2007
Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients
R.A. Rudick, G.R. Cutter, M. Baier, B. Weinstock-Guttman,...
Drugs
March 2007
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis
Richard A. Rudick, William H. Stuart, Peter A. Calabresi,...
Drugs
March 2007
Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Sean J. Pittock, Brian G. Weinshenker, John H. Noseworthy...
Drugs
March 2007
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Tarek A. Yousry, Eugene O. Major, Caroline Ryschkewitsch,...
Drugs
March 2007
Campath treatment suspended after serious risks found
Drugs
March 2007
Natalizumab for Relapsing Multiple Sclerosis
Drugs
February 2007
Stacking the Deck
Jim Giles
Drugs
February 2007
Wall Street and Clinical Trials
Robert Steinbrook
Drugs
February 2007
One drug trial, six men, disaster…
Shaoni Bhattacharya, Andy Coghlan
Drugs
November 2005
Clinical and MRI outcome after autologous hematopoietic stem cell transplantation in MS
A. Saiz, Y. Blanco, E. Carreras, J. Berenguer, M. Rovira,...
Drugs
November 2005
Patterns of cannabis use among patients with multiple sclerosis
A.J. Clark, M.A. Ware, E. Yazer, T.J. Murray, M.E. Lynch
Drugs
November 2005
Mycophenolate-Mofetil May Stabilize Patients with Progressive Multiple Sclerosis
Adrian Burton
Drugs
November 2005
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Annette Langer-Gould, Scott W. Atlas, Andrew W. Bollen, D...
Drugs
November 2005
Therapeutic potential of lovastatin in multiple sclerosis
Armando Sena, Rui Pedrosa, M. Graça Morais
Drugs
November 2005
Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre
B.D. Dubois, E. Keenan, B.E. Porter, R. Kapoor, P. Rudge,...
Drugs
November 2005
Progressive Multifocal Leukoencephalopathy Complicating Treatment with Natalizumab and Interferon Beta-1a for Multiple Sclerosis
B.K. Kleinschmidt-DeMasters, Kenneth L. Tyler
Drugs
November 2005
FTY720, a novel once-daily oral medication, shows promising results in treatment of multiple sclerosis
Bettina Maunz, John Gilardi
Drugs
November 2005
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon B
Bibiana Bielekova, Nancy Richert, Thomas Howard, Gregg Bl...
Drugs
November 2005
Conflicts of interest in medical science: peer usage, peer review and ‘CoI consultancy’
Bruce G. Charlton
Drugs
November 2005
Natalizumab and Progressive Multifocal Leukoencephalopathy
Burt Adelman, Alfred Sandrock, Michael A. Panzara
Drugs
November 2005
Intravenous immunoglobulin in neurological disease: a specialist review
C. M. Wiles, P. Brown, H. Chapel, R. Guerrini, R.A.C. Hug...
Drugs
November 2005
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine
C. Mainero, M. Inghilleri, P. Pantano, A. Conte, D. Lenzi...
Drugs
November 2005
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
C. Polman, F. Barkhof, M. Sandberg-Wollheim, A. Linde, O....
Drugs
November 2005
Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis
Cathie L.M. Sudlow, Carl E. Counsell
Drugs
November 2005
Statins for the treatment of multiple sclerosis: cautious hope
Chris H. Polman, Joep Killestein
Drugs
November 2005
Disease modifying therapies in multiple sclerosis
D.S. Goodin, E.M. Frohman, G.P. Garmany, Jr., J. Halper, ...
Drugs
November 2005
Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis
Dana Ekstein, Eduard Linetsky, Oded Abramsky, Dimitrios K...
Drugs
November 2005
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
David H. Miller, Omar A. Khan, William A. Sheremata, Lanc...
Drugs
November 2005
Interferons in relapsing remitting MS
Douglas S. Goodin
Drugs
November 2005
A randomized, double-blind, placebocontrolled MRI study of anti–herpes virus therapy in MS
E. Bech, J. Lycke, P. Gadeberg, H.J. Hansen, C. Malmeströ...
Drugs
November 2005
Cholesterol drug counters MS symptoms in mice
E.J. Mundell
Drugs
November 2005
Fulminant liver failure during interferon beta treatment of multiple sclerosis
E.M. Yoshida, S.L. Rasmussen, U.P. Steinbrecher, S.R. Erb...
Drugs
November 2005
New systems for delivery of drugs to the brain in neurological disease
Eain M. Cornford, Marcia E. Cornford
Drugs
November 2005
Arthritis Medicines and Cardiovascular Events—“House of Coxibs"
Eric J. Topol
Drugs
November 2005
Additive effect of the combination of glatiramer acetate and minocycline in a model of MS
Fabrizio Giuliani, Luanne M. Metz, Tammy Wilson, Yan Fan,...
Drugs
November 2005
When marketing and science intersect: Do patients with MS benefit?
Fred D. Lublin
Drugs
November 2005
Immunotherapies: cause for measured optimism
Gary T. Jennings, Martin F. Bachmann
Drugs
November 2005
Neutralizing anti-IFN-B antibodies
Gavin Giovannoni, Andrew Goodman
Drugs
November 2005
Preventing multiple sclerosis?
George C Ebers
Drugs
November 2005
Transdermal Histamine in Multiple Sclerosis, Part Two: A Proposed Theoretical Basis for Its Use.
George Gillson, Jonathan V. Wright, Elaine DeLack, George...
Drugs
November 2005
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn’s Disease
Gert Van Assche, Marc Van Ranst, MRaf Sciot, Bénédicte Du...
Drugs
November 2005
Liver injury associated with the B-interferons for MS
Gordon S. Francis, Neil Kaplowitz, Enrica Alteri
Drugs
November 2005
Interferons in relapsing remitting multiple sclerosis: a systematic review
Graziella Filippini, Luca Munari, Barbara Incorvaia, Geor...
Drugs
November 2005
Future Immunotherapies in Multiple Sclerosis
Gregg Blevins, Roland Martin
Drugs
November 2005
Randomized, comparative study of interferon B-1a treatment regimens in MS
H. Panitch, D.S. Goodin, G. Francis, P. Chang, P.K. Coyle...
Drugs
November 2005
Tackling multiple sclerosis
Hartmut Wekerle
Drugs
November 2005
The Lessons of Vioxx — Drug Safety and Sales
Henry A. Waxman
Drugs
November 2005
Remission in models of type 1 diabetes by gene therapy using a single-chain insulin analogue
Hyun Chul Lee, Su-Jin Kim, Kyung-Sup Kim, Hang-Cheol Shin...
Drugs
November 2005
Modafinil Is Safe and Effective Treatment for MS-Related Fatigue
J. Neurol
Drugs
November 2005
Copaxone’s effect on MRI-monitored disease in relapsing MS is reproducible and sustained
J.S. Wolinsky, G. Comi, M. Filippi, D. Ladkani; S. Kadosh...
Drugs
November 2005
COX-2 Inhibitors — A Lesson in Unexpected Problems
Jeffrey M. Drazen
Drugs
November 2005
Patients at Risk
Jeffrey M. Drazen
Drugs
November 2005
Daclizumab Zenapax inhibits early interleukin-2 receptor / signal transduction events
Jens Goebela, Erica Stevens, Kathy Forrest, Thomas L. Ros...
Drugs
November 2005
Financial Indigestion
Jerome P. Kassirer
Drugs
November 2005
FDA Standards — Good Enough for Government Work?
Jerry Avorn
Drugs
November 2005
Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis
Jim Chilcott, Chris McCabe, Paul Tappenden, Anthony O’Hag...
Drugs
November 2005
Marijuana as a treatment for epilepsy and multiple sclerosis?
Joseph I. Sirven, Anne T. Berg
Drugs
November 2005
Progressive Multifocal Leukoencephalopathy and Natalizumab — Unforeseen Consequences
Joseph R. Berger, Igor J. Koralnik
Drugs
November 2005
Cost of Managing an Episode of Relapse in Multiple Sclerosis in the United States
Judith A O'Brien, Alexandra J Ward, Amanda R Patrick, Jai...
Drugs
November 2005
Needed in MS Evidence, not EVIDENCE
Karl Kieburtz, Michael McDermott
Drugs
November 2005
Current Therapy of Multiple Sclerosis
Kenneth P. Johnson, J. Richard Baringer
Drugs
November 2005
Intramuscular Interferon Beta-1A Therapy Initiated During A First Demyelinating Event In Multiple Sclerosis
Lawrence D. Jacobs, Roy W. Beck, MJack H. Simon, R. Phill...
Drugs
November 2005
Multiple Sclerosis: Update on Treatment
Lawrence M. Samkoff
Drugs
November 2005
Biological containment of genetically modified Lactobacillus lactis for intestinal delivery of human interleukin 10
Lothar Steidler, Sabine Neirynck, Nathalie Huyghebert, Ve...
Drugs
November 2005
Minocycline Reduces Gadolinium-Enhancing Magnetic Resonance Imaging Lesions in Multiple Sclerosis
Luanne M. Metz, Yunyan Zhang, Michael Yeung, David G. Pat...
Drugs
November 2005
Lack of evidence for use of glatiramer acetate in multiple sclerosis
Luca M. Munari, Graziella Filippini
Drugs
November 2005
The Janus face of CNS-directed autoimmune response: a therapeutic challenge
Ludwig Kappos, Petra Duda
Drugs
November 2005
Drug researchers leak secrets to Wall St.
Luke Timmerman, David Heath
Drugs
November 2005
A randomized, double-blind, dosecomparison study of weekly interferon B-1a in relapsing MS
M. Clanet, E.W. Radue, L. Kappos, H.P. Hartung, R. Hohlfe...
Drugs
November 2005
Effect of glatiramer acetate on MS lesions enhancing at different gadolinium doses
M. Rovaris, M. Codella, L. Moiola, A. Ghezzi, M. Zaffaron...
Drugs
November 2005
Design of effective immunotherapy for human autoimmunity
Marc Feldmann, Lawrence Steinman
Drugs
November 2005
Suppressing immunity in advancing MS
Mark S. Freedman, Harold L. Atkins
Drugs
November 2005
Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis
Masha Fridkis-Hareli, Laura Santambrogio, Joel N.H. Stern...
Drugs
November 2005
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
Massimo Filippi, Marco Rovaris, Matilde Inglese, Frederik...
Drugs
November 2005
Treatment of severe autoimmune disease by stem-cell transplantation
Megan Sykes, Boris Nikolic
Drugs
November 2005
Immunomodulation Of Autoimmune And Inflammatory Diseases With Intravenous Immune Globulin
Michel D. Kazatchkine, Srini V. Kaveri
Drugs
November 2005
Therapy with glatiramer acetate for multiple sclerosis
Munari L., Lovati R., Boiko A.
Drugs
November 2005
Treatment of Multiple Sclerosis with the Pregnancy Hormone Estriol
Nancy L. Sicotte, Stephanie M. Liva, Rochelle Klutch, Pau...
Drugs
November 2005
Glatiramer Acetate Therapy: The Plot Thickens
Nitin J. Karandikar, Michael K. Racke
Drugs
November 2005
A prospective, open-label treatment trial to compare the effect of IFN b-1a (Avonex), IFNb-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis
O. A. Khana, A. C. Tselis, J. A. Kamholz, J. Y. Garbern, ...
Drugs
November 2005
Statins as immunomodulators; Comparison with interferon-β1b in MS
O. Neuhaus, S. Strasser-Fuchs, F. Fazekas, B.C. Kieseier,...
Drugs
November 2005
Using stem cells in multiple sclerosis therapies
P.A. Muraro, R. Cassiani-Ingoni, R. Martin
Drugs
November 2005
Novantrone Adverse Effects
Paul Lammers
Drugs
November 2005
Key issues in the diagnosis and treatment of multiple sclerosis
Paul O’Connor
Drugs
November 2005
Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis
Petra W. Duda, Mascha C. Schmied, Sandra L. Cook, Jeffrey...
Drugs
November 2005
Bystander Modulation of Chemokine Receptor Expression on Peripheral Blood T Lymphocytes Mediated by Glatiramer Therapy
Rameeza Allie, Lina Hu, Katherine M. Mullen, Suhayl Dhib-...
Drugs
November 2005
Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: From pipe dreams to (therapeutic) pipelines
Reinhard Hohlfeld, Hartmut Wekerle
Drugs
November 2005
Growth factor treatment of demyelinating disease: at last, a leap into the light
Richard M. Ransohoff, Charles L. Howe, Moses Rodriguez
Drugs
November 2005
New directions in MS therapeutics: vehicles of hope
Robert J. Fox, Richard M. Ransohoff
Drugs
November 2005
Financial Conflicts of Interest and the Food and Drug Administration’s Advisory Committees
Robert Steinbrook
Drugs
November 2005
Drug Interactions with Grapefruit Juice: An Evidence-Based Overview
Sam Shimomura, Sompon Wanwimolruk, Jack J. Chen
Drugs
November 2005
Immune Modulation in Multiple Sclerosis Patients Treated with the Pregnancy Hormone Estriol
Samantha S. Soldan, Ana Isabel Alvarez Retuerto, Nancy L....
Drugs
November 2005
Silencing Autoimmunity in Multiple Sclerosis, Lupus, and Rheumatoid Arthritis
Sara M. Mariani
Drugs
November 2005
Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS
Scott S. Zamvil, Lawrence Steinman
Drugs
November 2005
Is nalalizumab a breakthrough in the treatment of MS?
Sheila A. Doggrell
Drugs
November 2005
Bias, not conflict of interest, is the enemy
Steven R. Schwid, Robert A. Gross
Drugs
November 2005
Preventive Medicine, Properly Practiced
Susan M. Love
Drugs
November 2005
Oral simvastatin treatment in relapsing-remitting multiple sclerosis
Timothy Vollmer, Lyndon Key, Valerie Durkalski, William T...
Drugs
November 2005
Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy
Tjalf Ziemssen, Tania Kumpfel, Wolfgang E. F. Klinkert, O...
Drugs
November 2005
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial
Valentina Tomassini, Carlo Pozzilli, Emanuela Onesti, Pat...
Drugs
November 2005
Low dose naltrexone therapy in MS
Y.P. Agrawal
Drugs
November 2005
Nascobal
Drugs
November 2005
Prescription for change
Drugs
November 2005
Rebif Adverse Reactions
Drugs
November 2005
Treatment Optimization for Multiple Sclerosis: An Expert Interview With Mark Freedman, MD
